Test shorter blood-thinner use versus standard after heart attack
Part of Heart & circulation clinical trials.
This trial compares two ways of using anti-platelet (blood-thinner) medicines after a specific kind of heart attack (STEMI) treated with a stent. It aims to see if switching sooner to one medicine (instead of two for longer) works just as well and may reduce risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a STEMI heart attack and are scheduled for stent treatment (PCI)
- Your ECG showed specific heart attack signs, or you had a new/likely new left bundle branch block
- If you had more than one blockage, they treated only the “culprit” blockage during the first procedure
- At 30–45 days, you must have taken both blood thinners exactly as prescribed with no major problems
- Your stent procedure must have successfully opened the target areas (residual narrowing under 30%) and, if needed, other important blockages were fully treated within 15 days
- You must be able to take aspirin and a P2Y12 tablet (like prasugrel) and have safe blood counts (platelets not too low, hemoglobin not too low)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a shorter course of two blood thinners, guided by an ultrasound inside the arteries, is as safe and effective as the standard longer course in people who have had a stent placed for a heart attack or chest pain.
This study tests if doctors can safely use special eye scans (OCT) or angiography to decide when to stop taking two blood thinners (DAPT) after a heart attack and stent placement. It aims to reduce bleeding risks while still protecting your heart.
This trial tests if a lower dose of prasugrel, taken alone (without aspirin), is safe and works well for people who have had a stent placed for chest pain or a heart attack. It might be an option for those who need to simplify their medication routine.
This trial tests an algorithm (computer-guided plan) to choose the best “dual antiplatelet therapy” (two blood-thinning medicines) after a coronary stent. It aims to improve outcomes after the procedure while reducing avoidable problems from the medicines.
This trial tests a shorter course of dual antiplatelet therapy (aspirin plus ticagrelor) after stent placement, switching early to just ticagrelor alone. It aims to see if this approach can safely reduce bleeding risks while still protecting against heart problems in people with stable coronary artery disease.
This trial tests if a very short course of dual antiplatelet therapy (two blood thinners) after getting a stent is safe and effective for patients aged 65 and older. The goal is to reduce bleeding risks while still preventing heart attacks.
Hear when a new Dual Antiplatelet Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.